Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly semaglutide dose-response in overweight patients with type 2 diabetes
2022-000882-41Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to week 40. Started Jun 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on 2022-000882-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000882-41.